On 11 September 2026 the FDA approved a supplement to an abbreviated new drug application for ethosuximide held by Chartwell RX. The notice does not state what the supplement changes; supplements to generic applications commonly cover labelling, manufacturing or packaging.
Ethosuximide remains a first-choice drug for childhood absence epilepsy. Nothing in this notice changes how it is prescribed, and it has no bearing on Indian supply or CDSCO status, which are not stated.
- This is an FDA action on one generic product's application, not a new indication or safety finding.
- No change to ethosuximide prescribing follows from it.
- Ethosuximide does not induce liver enzymes and does not reduce hormonal contraceptive efficacy.
- Supply of ethosuximide in India is not addressed by this notice.
Why it matters
It confirms continued generic supply in the USA of a drug that is often hard to obtain.
Don't overread it
A licence supplement is not a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free